Key Takeaways
- A translated pathology report tells a Chinese team what another pathologist concluded. A pathology review asks a new pathologist to examine the available material and issue an interpretation.
- The review should answer a treatment question: tumour type, grade, margins, lymph-node findings, invasion, biomarker adequacy or another feature that changes management.
- Cancer classification evolves. WHO tumour classifications increasingly combine morphology and molecular findings, so terminology from an older report may need mapping rather than simple word-for-word translation.[3]
- Protect the specimen. Decide which stains or molecular tests matter now before cutting more sections from a small biopsy.
- Do not begin an irreversible treatment from an unresolved patient, specimen or diagnosis mismatch merely to preserve a travel date. The treating team decides how urgently review must be completed.
Content
Cancer treatment is chosen for a diagnosis, not for an image that “looks suspicious.” Surgery, systemic therapy and radiotherapy can all depend on what the tumour is, where it came from and which features the specimen truly demonstrates.
For an international patient, pathology review in China is most valuable when it is designed as part of the treatment decision. Sending slides without a clinical question can produce an accurate consultation that still fails to answer what the oncologist needs.
Decide What the Review Must Confirm
Before any material moves, the oncologist and reviewing pathologist should identify the decision at stake. Common questions include:
- Is this malignant, and what is the tumour type or lineage?
- Is the lesion a new primary cancer, recurrence or metastasis from another site?
- What grade, invasion pattern, margin or lymph-node findings are established?
- Does the specimen meet criteria for a specific disease entity under current classification?
- Is enough viable tumour present for a treatment-defining biomarker?
- Does an older biomarker result still represent the current disease and treatment setting?
The WHO Classification of Tumours supplies international diagnostic standards and increasingly integrates histology with molecular pathology.[3] A difference in wording can therefore reflect a newer classification, additional evidence or a truly different interpretation. The reviewer should say which.
Know What a Pathology Report Can—and Cannot—Settle
A surgical pathology report may describe the specimen, microscopic diagnosis, tumour type, grade, margins, lymph nodes and other features. NCI explains that patients seeking a pathology second opinion commonly need to obtain slides and/or a paraffin block and contact the reviewing institution about availability, cost and shipping.[1]
Pathology does not replace the rest of staging. Tumour size in a resection, nodal findings and pathologic stage components may be reported, but distant spread and overall clinical stage can also require imaging, examination and other tests. Ask the oncology team to separate:
- diagnosis confirmed by tissue;
- pathologic features relevant to staging;
- clinical or imaging stage information;
- predictive biomarkers;
- items still unknown.
This prevents a pathology review from being misrepresented as a complete cancer reassessment.
Assemble a Cancer-Specific Review Set
The reviewing service should specify its requirements. A useful set often contains:
The entire report history
Include preliminary, final, amended and addendum reports in the source language. Place translations beside—not over—the originals. Record which version the treating team previously used.
Source material
List every slide, paraffin block, cytology preparation, cell block or digital whole-slide image sent. Include the accession number, specimen site, procedure and collection date. China’s pathology-department guidance requires systems for pathology slide and smear lending and consultation, and specifies core identifiers in diagnostic reports.[4]
The clinical map
Provide the relevant imaging location, operative or biopsy note, prior cancers, treatments given before sampling and the current oncology question. Neoadjuvant therapy can alter tumour appearance; a sampled liver lesion in a patient with two prior cancers cannot be interpreted safely from the words “liver mass” alone.
Existing ancillary studies
Attach immunohistochemistry, in-situ hybridisation, flow cytometry, cytogenetic and molecular reports with method, specimen and result. Do not reduce them to a hand-typed list of “positive” and “negative.”
Check the Chain Before Looking Down the Microscope
Match the patient name, accession number, anatomic site, side and date across the report, slide labels, operative note and imaging. If a lung report is paired with a block labelled from a lymph node, that may be correct—but the relationship must be documented.
Stop the review if an identity or site discrepancy cannot be reconciled. The source laboratory and receiving pathology department should resolve it in writing. A coordinator should not guess that two different spellings or accession numbers “must be the same.”
Ask for a Structured Cancer Diagnosis
Structured reporting helps clinicians find the elements that drive management. CAP cancer protocols define essential data elements for malignant-tumour reporting and are updated as classifications, staging and biomarker standards evolve.[2]
The review report should make clear:
- material actually examined;
- tumour classification and grade, when applicable;
- margin, invasion and lymph-node findings available from the specimen;
- whether the submitted material is representative and adequate;
- stains or tests performed in the reviewing laboratory;
- discrepancy from the outside report and its clinical significance;
- limitations and differential diagnosis;
- additional material or testing recommended.
A one-line “diagnosis confirmed” may be enough for a simple case, but not when treatment depends on a missing margin, subtype or biomarker.
Triage Tissue Around the Next Decision
Small biopsies are finite. Every recut, immunostain and molecular extraction consumes material. Before ordering a broad panel, ask the pathologist to estimate tumour amount and create a testing sequence.
A reasonable hierarchy may be:
- establish or confirm the tumour class;
- perform essential lineage or subtype stains;
- preserve material for biomarkers linked to the current treatment decision;
- reserve tissue for confirmatory or future testing when feasible.
The order varies by cancer. “More testing” is not automatically better if it exhausts the only block before a necessary companion test.
Interpret Biomarkers as Test–Specimen–Treatment Triples
NCI notes that biomarker testing can examine genes, proteins and other tumour features, but it may fail because tissue is insufficient, no useful marker is found, or tumour biology has changed over time.[5]
For every treatment-linked result, record:
- tumour type and treatment setting;
- specimen site and collection date;
- test method or platform;
- tumour adequacy and quality comments;
- exact result, score, threshold or variant;
- assay scope and important limitations;
- medicine or decision for which the result is being used.
Some tests are companion diagnostics paired with specific treatments. The FDA describes such a device as supplying information essential to the safe and effective use of its corresponding therapeutic product, with the applicable specimen, biomarker and medicine specified in labelling.[6] A “positive marker” from a different assay, specimen or disease context should not be treated as interchangeable without expert review.
A variant of uncertain significance is not a treatment instruction. A possible inherited finding on tumour testing may require confirmation from a normal sample and genetics counselling.
Handle Disagreement by Clinical Consequence
Do not summarise all discrepancies as “minor” or “major” without explaining why. Sort them by what changes:
- Terminology only: different words, same management.
- Classification refinement: a more specific entity, possibly affecting prognosis or testing.
- Treatment-relevant difference: grade, margin, receptor, molecular result or tumour origin changes the plan.
- Unresolved: material is insufficient or experts retain a differential diagnosis.
Ask whether another stain, molecular test, original block, subspecialty pathologist or new biopsy could resolve the issue. Preserve both the outside and China review reports; never replace the history with an edited PDF.
Connect Pathology to the Multidisciplinary Decision
NCI describes tumour review boards as groups of specialists who consider pathology and other tests together when planning treatment.[1] For a complex international case, the useful endpoint is an integrated note—not simply the pathologist’s report arriving in an inbox.
The oncology note should state:
- diagnosis being used for treatment;
- stage information and its sources;
- biomarkers accepted for the current decision;
- missing or pending information;
- whether the plan would change if a pending result differs;
- clinician responsible for deciding when treatment starts.
Plan Time and Cost in Two Phases
Separate review cost from follow-on testing cost. The first may include accessioning, slide review and a consultation report. The second may include recuts, stains, molecular tests, a new biopsy, courier, customs and material return.
Ask for milestones rather than one vague turnaround time:
- material received and reconciled;
- adequacy confirmed;
- preliminary question answered, if the service offers this;
- additional tests authorised;
- final report released;
- oncology plan documented;
- block and unused slides returned.
The treating clinician—not the travel agency—should decide whether waiting is safe. An urgent condition may require treatment while optional studies remain pending; a diagnosis or identity uncertainty may require delay before an irreversible intervention.
The Final Pre-Treatment Pathology Checklist
- [ ] Current diagnosis and terminology stated
- [ ] Material examined listed by accession and specimen
- [ ] Outside and review reports both preserved
- [ ] Stage-related pathology separated from clinical staging
- [ ] Treatment-defining biomarkers tied to method and specimen
- [ ] Tissue remaining and return plan recorded
- [ ] Discrepancies translated into clinical consequences
- [ ] Pending results assigned to a named clinician
- [ ] Oncology decision note completed before treatment
Medical disclaimer: This guide does not interpret a pathology specimen or decide cancer treatment. Pathology review, tissue use and treatment timing require case-specific decisions by qualified pathologists and the treating oncology team.
Related Hospitals
Link only a hospital whose relevant tumour-site pathology service confirms that it accepts outside material and can issue a formal consultation report. The original generic hospital list has been removed.
Related Treatments
Pathology may affect surgery, radiotherapy, chemotherapy, endocrine therapy, targeted therapy, immunotherapy and clinical-trial eligibility. A treatment link should be added only after the diagnosis and decision-defining evidence are established.
Related Guides
- Pathology and Laboratory Record Review Before Treatment in China
- Getting a Cancer Second Opinion in China
- How to Organise Medical Records Before Seeking Care in China
- How to Share CT, MRI and Other Imaging Files With a Chinese Hospital
- How to Find a Clinical Trial in China
FAQ
Is an English translation the same as a pathology second opinion?
No. Translation reproduces the existing report in another language. A pathology second opinion requires another pathologist to evaluate submitted slides, blocks or suitable digital material and issue an interpretation.[1]
Does every cancer need pathology review before treatment in China?
Not automatically. The treating team should decide whether review is required based on diagnostic confidence, treatment risk, specimen availability and how likely a new interpretation is to change care.
Can the pathology review change the cancer stage?
It can change pathologic features that contribute to stage, such as tumour or lymph-node findings. Overall clinical stage may also depend on imaging, examination and other evidence.
Should all available biomarker tests be ordered at once?
No. The pathologist and oncologist should prioritise tests relevant to the next decision and conserve limited tissue. Broad testing can be unhelpful if it uses the only specimen before an essential assay.[5]
Who decides whether treatment waits for the final report?
The treating oncologist should decide with pathology and other specialists, weighing the consequence of missing information against the risk of delaying therapy.
Sources
- US National Cancer Institute — Surgical Pathology Reports and Second Opinions
- College of American Pathologists — Current Cancer Reporting and Biomarker Protocols
- International Agency for Research on Cancer / WHO — Classification of Tumours
- National Health Commission of China — Guidelines for Construction and Management of Pathology Departments
- US National Cancer Institute — Biomarker Testing for Cancer Treatment
- US Food and Drug Administration — Authorized Companion Diagnostic Devices
Hero Image Review
- Decision: Approved and retained as hero-reviewed.png.
- Why: The visual pathway explicitly connects a report, microscope, cancer symbol and clinical discussion, matching the article’s patient-facing purpose.
- Risk check: The diagram is non-diagnostic and contains no readable specimen label, patient identifier, provider logo or outcome guarantee.